16.6: Research Use Investigational Use and Approved Use

Cell Culture Textbook (Biot 77 IVC) · LibreTexts

0%

Contents

    Text

    Size
    100%
    Theme
    Typeface
    Line length
    Spacing

    Read aloud

    How

    Speed: 1×
    Light up
    Highlight

    Symbols: Mulberry Symbols, © 2018–2026 Steve Lee, CC BY-SA 4.0 (licence, the set), the site's own copies.

    From LibreTexts, under CC BY-NC-SA 4.0, as the source states it; its equations are written in TeX, which the PDF shows typeset. This page at LibreTexts.

    16.6: Research Use Investigational Use and Approved Use

    Research use includes activities intended to develop knowledge, research oversight.pngsuch as measuring gene expression in a culture or testing a compound in a plate. A laboratory finding can support further research without supporting administration of that material to a person.

    Investigational clinical use studies an intervention in people under an appropriate clinical research framework. For many cellular and gene therapy products in the United States, an investigational new drug application, or IND, provides the regulatory framework for clinical investigation. An IND that is in effect allows the specified investigation to proceed; it is not marketing approval or proof of effectiveness.

    An approved product has undergone the applicable regulatory review for a defined use. Approval of one product does not establish that another preparation with a similar cell name, source, or claimed mechanism has the same quality or clinical benefit.

    The United States framework for human cells tissues and cellular and tissue-based products, or HCT/Ps, includes different regulatory pathways. Certain HCT/Ps that satisfy all applicable criteria can be regulated solely under section 361 of the Public Health Service Act and 21 CFR part 1271. Products that do not satisfy those criteria and are not within an applicable exception may be regulated as drugs, devices, and/or biological products requiring additional review.

    Minimal manipulation and homologous use are two criteria in that framework. Minimal manipulation has definitions related to the type of tissue or cells and relevant characteristics. Homologous use concerns whether the material performs the same basic function in the recipient as in the donor. Both terms have regulatory meanings; they are not everyday judgments about whether a procedure seems simple. Other criteria also matter.

    Autologous origin, a brief processing time, or a negative contamination screen does not by itself settle a product's regulatory status. The complete product and intended use need assessment. In particular, culture expansion or genetic modification should not be assumed to fit a pathway for minimally manipulated tissue.

    Laws and regulations establish applicable requirements. Guidance documents generally explain an agency’s current thinking and recommendations; a draft guidance is not a final requirement. Distinguish these sources when evaluating a proposed activity.

    A product label saying “research use” does not establish permission for clinical administration. The actual intended use and applicable rules matter. Likewise, registration of an establishment is different from product approval. Check the status of the specific product and application through authoritative sources.

    Attribution: Images AI-generated using ChatGPT Modified by Emalee Mackenzie, Irvine Valley College. Licensed under CC BY-NC-SA


    This page titled 16.6: Research Use Investigational Use and Approved Use was last modified on Wed, 21 Oct 2026 01:35:46 GMT and is shared under a CC BY-NC-SA 4.0 license and was authored, remixed, and/or curated by Emalee MacKenzie.